Symbicort Turbohaler + CHF 1535 pMDI Placebo

Symbicort Turbohaler + CHF 1535 pMDI Placebo is a combination therapy used in clinical trials, where the active drug is Symbicort Turbohaler (a dry powder inhaler containing budesonide and formoterol fumarate dihydrate) administered alongside a placebo pressurized metered dose inhaler (pMDI), known as CHF 1535 pMDI Placebo. Symbicort Turbohaler delivers two active ingredients: - Budesonide, an inhaled corticosteroid that reduces inflammation in the airways. - Formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow. This combination provides both anti-inflammatory and bronchodilatory effects for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The placebo component serves as a control in clinical studies to assess efficacy or safety of the active product[2][4][5][6].

Other names

budesonide and formoterol Turbuhalerbudesonide/formoterol fumarate dihydrate inhaler